These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 26285159)
21. [The study of the correlation of papillary thyroid carcinoma's invasion toward Ezrin and E-cadherin]. Liu C; Chen X; Gao Z; Liu Z; Tao X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Sep; 26(17):789-91, 795. PubMed ID: 23214316 [TBL] [Abstract][Full Text] [Related]
22. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490 [TBL] [Abstract][Full Text] [Related]
23. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma]. Hao Y; Jin C; Wang J Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609 [TBL] [Abstract][Full Text] [Related]
24. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721 [TBL] [Abstract][Full Text] [Related]
25. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters. Kombak FE; Özkan N; Uğurlu MÜ; Kaya H Turk Patoloji Derg; 2019; 35(2):83-91. PubMed ID: 30632125 [TBL] [Abstract][Full Text] [Related]
26. [Study of the correlation of papillary thyroid carcinoma's invasion with Ezrin, Moesin and E-Cadherin]. Tao XF; Liu C; Bai Y; Chen X Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Sep; 46(9):761-3. PubMed ID: 22177047 [TBL] [Abstract][Full Text] [Related]
27. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer. Lee J; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Jung SG; Lee EJ; Chung WY; Jo YS Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S683-90. PubMed ID: 26215201 [TBL] [Abstract][Full Text] [Related]
28. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785 [TBL] [Abstract][Full Text] [Related]
29. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma. Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590 [TBL] [Abstract][Full Text] [Related]
30. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Knauf JA; Ma X; Smith EP; Zhang L; Mitsutake N; Liao XH; Refetoff S; Nikiforov YE; Fagin JA Cancer Res; 2005 May; 65(10):4238-45. PubMed ID: 15899815 [TBL] [Abstract][Full Text] [Related]
31. Single BRAFV600E mutation is not associated with aggressive biological behavior in adolescent and pediatric papillary thyroid carcinoma. Zhou B; Lu X; Hei H; Zhang S; Li Y; Fang J; Qin J; Ge H Cancer Cytopathol; 2023 Nov; 131(11):716-723. PubMed ID: 37519275 [TBL] [Abstract][Full Text] [Related]
32. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774 [TBL] [Abstract][Full Text] [Related]
33. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. Cheng L; Jin Y; Liu M; Ruan M; Chen L Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638 [TBL] [Abstract][Full Text] [Related]
34. [Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance]. Cheng Y; Meng Y; Liang Z; Yang C; Luo Y; Cui Q Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):189-94. PubMed ID: 26268754 [TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077 [TBL] [Abstract][Full Text] [Related]
36. Overexpression of HIF-2α, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma. Wang N; Luo HJ; Yin GB; Dong CR; Xu M; Chen GG; Liu ZM Clin Dev Immunol; 2013; 2013():589423. PubMed ID: 24288553 [TBL] [Abstract][Full Text] [Related]
37. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704 [TBL] [Abstract][Full Text] [Related]
38. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis. Ma YJ; Deng XL; Li HQ J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933 [TBL] [Abstract][Full Text] [Related]
39. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation. Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809 [TBL] [Abstract][Full Text] [Related]
40. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]